|
**Overview**: JAK2 V617F Exon 12 Panel**Introduction**: The JAK2 V617F Exon 12 Panel is a diagnostic tool designed to detect JAK2 mutations in myeloproliferative neoplasms using whole blood samples. In India, myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) affect ~1-3 per 100,000 annually, with JAK2 V617F mutation present in ~95 percent of PV, ~50-60 percent of ET/PMF, and exon 12 mutations in ~3-5 percent of JAK2 V617F-negative PV. High morbidity from underdiagnosis in rural/low-SES patients with unexplained polycythemia, thrombocytosis, or splenomegaly, limited molecular labs, delayed hydroxyurea/ruxolitinib leading to thrombosis, hemorrhage, or transformation to leukemia. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs PCR for JAK2 V617F and exon 12 mutations over 1-2 days with high sensitivity/specificity, valuable for confirming driver mutations and guiding WHO classification. This diagnostic falls under genetic cancer screening and targets patients with elevated hematocrit/platelets or MPN suspicion, addressing accurate detection to initiate cytoreductive therapy and thromboprophylaxis. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise molecular diagnosis and reducing MPN complications. Its whole blood-based approach ensures reliable mutation detection.**Other Names**: JAK2 V617F Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology/oncology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: JAK2 V617F discovery 2005; in India, routine in MPN workup.**Purpose**: The test assesses 2 parameters including JAK2 V617F mutation to guide MPN screening, confirm driver mutation, inform cytoreductive therapy.**Test Parameters**: 1. JAK2 V617F Mutation, 2. JAK2 Exon 12 Mutation.**Pretest Condition**: No fasting required; patients should report polycythemia or thrombocytosis.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on hemoglobin/platelet levels, thrombosis history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed MPN including thrombosis/leukemia, benefits of mutation detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive V617F/exon 12 confirms MPN driver mutation, necessitating specialist input.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: CALR/MPL, bone marrow biopsy for confirmation.**Test Limitations**: Detects JAK2 only; comprehensive approach required.**References**: Indian Journal of Hematology 2024, MPN Studies India 2023. |
